^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    letrozole

    i
    Other names: CGP 20267, CGS 20267, CGS20267
    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    4d
    OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=510, Recruiting, Olema Pharmaceuticals, Inc. | N=370 --> 510
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ESR1 mutation
    |
    fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)
    5d
    FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov)
    P2/3, N=260, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    ER positive • MSI-H/dMMR
    |
    Tyvyt (sintilimab) • letrozole • triptorelin • megestrol
    5d
    HCC 21-208: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov)
    P1, N=50, Recruiting, Finn, Olivera, PhD | Trial completion date: Aug 2028 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    tamoxifen • letrozole • anastrozole • exemestane • Hiltonol (poly-ICLC)
    6d
    Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruth O'Regan | Trial completion date: Jan 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    6d
    Protective Effects of Hesperidin on Letrozole-Induced Neurotoxicity: Involvement of Oxidative Stress, Apoptotic Signaling, and Inflammation. (PubMed, J Biochem Mol Toxicol)
    These findings indicate that hesperidin confers neuroprotection by restoring redox balance, regulating apoptosis, and suppressing inflammation in letrozole-induced neurotoxicity. Further studies are warranted to elucidate the precise molecular mechanisms and potential therapeutic applications of hesperidin in letrozole-induced neurotoxicity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    HR positive
    |
    letrozole
    6d
    Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report. (PubMed, Front Oncol)
    At last follow-up (OS: 108 months), she maintained SD with minimal toxicity. This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.
    Journal
    |
    ER (Estrogen receptor)
    |
    HR positive
    |
    letrozole • megestrol
    6d
    2022P002556-ENC-MONALEESA-2: Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=2495, Completed, Shirley Vichy Wang | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Kisqali (ribociclib) • letrozole
    7d
    FELINE: Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (clinicaltrials.gov)
    P2, N=121, Active, not recruiting, Qamar Khan | Trial completion date: Apr 2023 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • letrozole
    8d
    GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Gynecologic Oncology Group | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib) • letrozole
    13d
    Comparison of frozen embryo transfer outcomes in hormonal vs. mild stimulation protocols in polycystic ovary syndrome women: A randomized controlled trial. (PubMed, Int J Reprod Biomed)
    In HRT, oral estradiol followed by injectable progesterone was used; in MOS, letrozole +  follicle-stimulating hormone stimulation continued until follicle    17 mm and endometrium     7.5 mm, then human chorionic gonadotropin was given. However, the number of clinical pregnancies (p = 0.045) and the number of successful pregnancies (p = 0.049) were significantly higher in the MOS group compared to the HRT group. This study showed that MOS achieved higher clinical and successful pregnancy rates than HRT in women with PCOS.
    Journal
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • LIFR (LIF Receptor Subunit Alpha) • LIF (LIF Interleukin 6 Family Cytokine)
    |
    letrozole
    13d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    14d
    Characteristic Hepatic Atrophy in Abemaciclib-Induced Liver Injury: A Comparative Review of Three Cases. (PubMed, Hepatol Res)
    This report is the first highlighting the imaging characteristics of rapid-onset hepatic atrophy associated with abemaciclib-induced liver injury. These findings may provide useful insights for distinguishing abemaciclib-induced liver injury from other etiologies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole